Effects of Angiotensin Converting Enzyme (ACE) Inhibitors Versus Candesartan in Reducing Cardiovascular Events in Primary Treatment of Hypertension (ARBACE)
Status
Completed
Conditions
Hypertension
Cardiovascular Disease
Details and patient eligibility
About
The planned Study will be a retrospective study on the effect of ACE's vs. candesartan on cardiovascular events and on health economic effects in a "real life" setting in Sweden.
Enrollment
50,000 patients
Sex
All
Ages
17+ years old
Volunteers
No Healthy Volunteers
Inclusion criteria
- all patients found in electronic patient journals at the participating centres, who were prescribed either ACEis (ATC-C09A-B) or ARBs (C09C-D) for hypertension from 1 January 1999 - 31 December 2007. The first date of such a prescription starts the observation time and is called the index prescription.
Exclusion criteria
- No history of cardiovascular disease.
- Ongoing malignancy
Trial design
50,000 participants in 2 patient groups
ACE
Description:
Patients treated for hypertension with ACEs without CVD
Candesartan
Description:
Patients treated for hypertension with candesartan without CVD
Trial contacts and locations
56
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems